- Home
- ORIC vs EU Comparison
ORIC vs EU Comparison
Compare ORIC & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORIC | EU |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Metals and Minerals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 973.9M | 503.7M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ORIC | EU |
|---|---|---|
| Price | $8.12 | $2.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | ★ $19.50 | $4.00 |
| AVG Volume (30 Days) | 1.5M | ★ 2.9M |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $44,142,000.00 |
| Revenue This Year | N/A | $22.24 |
| Revenue Next Year | N/A | $86.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.90 | $1.01 |
| 52 Week High | $14.93 | $4.19 |
Technical Indicators
Market Signals| Indicator | ORIC | EU |
|---|---|---|
| Relative Strength Index (RSI) | 20.00 | 50.17 |
| Support Level | $10.45 | $2.28 |
| Resistance Level | $12.50 | $2.46 |
| Average True Range (ATR) | 0.70 | 0.20 |
| MACD | -0.24 | -0.02 |
| Stochastic Oscillator | 1.33 | 49.06 |
Price Performance
Historical ComparisonAbout ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.